Quantum-Si incorporated (QSI)
| Market Cap | 197.33M |
| Revenue (ttm) | 2.44M |
| Net Income (ttm) | -101.34M |
| Shares Out | 216.37M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,159,351 |
| Open | 0.890 |
| Previous Close | 0.900 |
| Day's Range | 0.885 - 0.940 |
| 52-Week Range | 0.691 - 3.100 |
| Beta | 3.09 |
| Analysts | Buy |
| Price Target | 1.00 (+9.65%) |
| Earnings Date | May 7, 2026 |
About QSI
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer’s protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-... [Read more]
Financial Performance
In 2025, Quantum-Si incorporated's revenue was $2.44 million, a decrease of -20.34% compared to the previous year's $3.06 million. Losses were -$101.34 million, 0.33% more than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for QSI stock is "Buy." The 12-month stock price target is $1.0, which is an increase of 9.65% from the latest price.
News
Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Successful Sequencing on Integrated Proteus™ Instruments.
Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report First Quarter 2026 Financial Results on May 7, 2026.
Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting.
Quantum-Si Announces New Manuscript Demonstrating the Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces New Manuscript Demonstrating Value of Single-molecule Protein Sequencing to Aid in Identifying New Cancer Treatment Strategies.
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System.
Quantum-Si Announces the Start of the Proteus™ Roadshow
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Start of the Proteus™ Roadshow.
Quantum-Si Shares Slip After Q4 Revenue Miss
Quantum-Si, Inc. (NASDAQ: QSI) shares moved lower in Tuesday's extended trading after the company released its fourth-quarter earnings report, missing Street revenue estimates.
Quantum-Si incorporated Earnings Call Transcript: Q4 2025
2026 will be a transition year with revenue mainly from consumables, limited new instrument sales, and a focus on preparing for the Proteus launch. Financial discipline is maintained, with strong cash reserves and lower gross margins expected due to revenue mix.
Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results.
Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026.
Quantum-Si Announces the Release of Two New Manuscripts Demonstrating the Value of Single-Molecule Protein Sequencing in Clinical Proteomics and Pathogen & Toxin Detection
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Release of Two New Manuscripts.
Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Launch of New Version 3 Library Preparation Kit and a Suite of Data Analysis Tool Enhancements.
Quantum-Si incorporated Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
Proteus, a next-generation protein sequencing platform, is on track for a 2026 launch, offering major architectural advances for scalability and cost efficiency. Early data show performance exceeding current systems, with commercialization strategies and financial resources in place to support growth.
Quantum-Si Highlights Significant Development Advancements for Proteus™ and Industry Leading Technology Pipeline at Investor & Analyst Day
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Highlights Significant Development Advancements for ProteusTM and Industry Leading Technology Pipeline at Investor & Analyst Day.
Quantum-Si incorporated Transcript: Investor Day 2025
Proteus introduces a scalable, automated protein sequencing platform with a roadmap to detect all 20 amino acids and broad PTM coverage by 2027. The system targets high-value applications, offers lower cost and higher throughput, and is set for commercial launch at the end of 2026, with early access and upgrade programs planned.
Quantum-Si to Highlight Significant Proteus™ Platform Development Progress and Provide Insights into the Company's Industry Leading Technology Pipeline at Investor & Analyst Day
BRANFORD, Conn.--(BUSINESS WIRE)--QSI to Highlight Significant Proteus™ Platform Dev Progress & Provide Insights into Company's Industry Leading Tech Pipeline at Investor & Analyst Day.
Quantum-Si incorporated Earnings Call Transcript: Q3 2025
Q3 2025 revenue was $552,000, with gross margin at 35% and continued capital market headwinds, especially in academia. Strategic placements expanded the install base, and the Proteus platform reached a key prototype milestone. Cash and investments stood at $230.5 million.
Quantum-Si Reports Third Quarter 2025 Financial Results
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Third Quarter 2025 Financial Results. Announces Successful Sequencing on Prototype Proteus Unit, Development Program is On-Track.
Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.
Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025.
Quantum-Si to Host Investor & Analyst Event in New York City on November 19, 2025
BRANFORD, Conn--(BUSINESS WIRE)--Quantum-Si to Host Investor & Analyst Event in New York City on November 19, 2025.
Quantum-Si incorporated Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The event highlighted progress on the Proteus platform, targeting a prototype by year-end and commercial launch next year. Market expansion into biopharma and government sectors, ongoing product and software innovation, and a strong financial position with disciplined spending were emphasized.
Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces the Launch of V4 Sequencing Kit, Expanding Proteome Coverage and Unlocking New Applications for Protein Sequencing.
Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the H.C. Wainwright 27th Annual Global Investment Conference.